



## Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences

Nov 12, 2024

CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced management's participation in the Jefferies London Healthcare Conference, the 7<sup>th</sup> Annual Evercore HealthCONx Conference, and the Citi Global Healthcare Conference. With an initial focus in oncology, Foghorn's Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.

### Jefferies London Healthcare Conference

- Fireside Chat: Tuesday, November 19, 2024, at 11:30 a.m. GMT in London, UK
- Foghorn Presenter: Adrian Gottschalk, President and Chief Executive Officer
- Please find a link to the webcast [here](#)
- Management will also participate in one-on-one meetings on Tuesday, November 19

### 7<sup>th</sup> Annual Evercore HealthCONx Conference

- Fireside Chat: Tuesday, December 3, 2024, at 1:20 p.m. EST in Coral Gables, Florida
- Foghorn Presenter: Adrian Gottschalk, President and Chief Executive Officer
- Please find a link to the webcast [here](#)
- Management will also participate in one-on-one meetings on Tuesday, December 3

### Citi Global Healthcare Conference

- Management will participate in one-on-one meetings on Wednesday, December 4 in Miami, Florida

A webcast of both fireside chats can be accessed under "Events & Presentations" in the Investors section of the Company's website, [www.foghornrx.com](http://www.foghornrx.com), and will be available for 30 days.

### About Foghorn Therapeutics

Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at [www.foghornrx.com](http://www.foghornrx.com) for more information on the Company, and follow us on [X](#) (formerly Twitter) and [LinkedIn](#).

### Contact:

Karin Hellsvik, Foghorn Therapeutics Inc.  
[khellsvik@foghornrx.com](mailto:khellsvik@foghornrx.com)